Sat Kartar (SATKARTAR) – Share Price & Analysis

Price ₹177.45, Market Cap 279.39 (Cr), P/E 20.28x. Score: 47.7/100.

Financial Ratios PE Ratio Shareholding Dividend Quarterly Results Financial Statements

Sat Kartar Stock Price Today (NSE: SATKARTAR)

Sat Kartar

SATKARTARPharmaceuticals

₹177.45+₹0.00 (+0.00%)

As on 27 Apr 2026, 05:54 pm ISTMarket Closed

Fundamental Score

...

Sat Kartar Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Sat Kartar share price today is ₹177.45, up +0.00% on NSE/BSE as of 27 April 2026. Sat Kartar (SATKARTAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹279.39 (Cr). The 52-week high for SATKARTAR share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 20.28x, SATKARTAR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 32.04% and a debt-to-equity ratio of 0.04.

Sat Kartar Share Price Chart — NSE/BSE Historical Performance

No data

High

₹177.45

Low

₹177.45

Volume

Change

+0.00%

AI Research Briefing

Micro-cap Ayurveda play attempting a risky pivot to healthcare services; liquidity a key concern.

Research Confidence

6.0/10Moderate

MICRO-CAP DARK HORSEConsolidation; 1M: -8.91%, 3M: 1.4%, 6M: 6.04%.Expensive; P/E of 20.28x vs Industry P/E of 31.77x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Sat Kartar Life (formerly Sat Kartar Shopping) announced an Extra Ordinary General Meeting (EGM) to be held on May 13, 2026. The purpose of the meeting was not specified in the initial announcement. The company also confirmed it is not a Large Corporate, with outstanding borrowing of ₹2.39 Cr as of March 31, 2026. Sat Kartar Life entered into a strategic Memorandum of Understanding with Jeena Sikho Lifecare Limited to integrate digital patient engagement with Ayurveda treatment infrastructure.

CORE STORY (THE REAL GAME)

Sat Kartar Life is attempting to transform from a commerce-led wellness enterprise to a diversified, life-centric healthcare ecosystem, focusing on Ayurvedic science and research-led wellness products. The core narrative is a shift towards preventive wellness and holistic care, aligning with the government's push for traditional Indian wellness systems.

WHAT IS DRIVING THE STOCK

Strategic Collaboration: The partnership with Jeena Sikho Lifecare aims to expand patient access to organized Ayurveda healthcare services and deepen engagement across the patient care lifecycle.

Rebranding: The corporate rebranding from Sat Kartar Shopping to Sat Kartar Life signals a strategic shift towards healthcare-led growth.

Financial Performance: The company has demonstrated good revenue growth (46.40% over the past 3 years) and has been maintaining healthy ROE (85.14% over the past 3 years) and ROCE (63.00% over the past 3 years).

BULL vs BEAR

Bull:The shift towards a healthcare-focused business model, combined with strategic collaborations and government support for Ayurveda, could drive long-term growth and improve profitability.

Bear:Micro-cap SME with potential liquidity risks. Reliance on outsourced manufacturing and a D2C model creates vulnerability. Shift to healthcare services requires execution. FII selling pressure.

WHAT MARKET IS PRICING

The market is pricing in the narrative of a successful transition from a shopping-focused company to a healthcare and wellness provider. The risk is that the market is overestimating the speed and success of this transition.

BOTTOM LINE

Sat Kartar Life is a micro-cap bet on the future of Ayurvedic healthcare, but liquidity risk and execution challenges loom large.

Why Now

Strategic MOU with Jeena Sikho Lifecare
Corporate rebranding to Sat Kartar Life
Government support for Ayurveda

Potential Catalysts

Successful integration of digital patient engagement with Ayurveda treatment infrastructure
Expansion of Ayush-approved hospitals and wellness centers
Positive earnings surprises

Key Risks

Micro/SME cap implies liquidity risk
High promoter holding limits float
FII selling pressure

Institutional Activity

FII reduced stake by 5.87%.

Macro Context

Government support for AYUSH and the Ayurvedic industry provides a tailwind.

Cash Flow Quality

No Free Cash Flow data available.

3–6 Month Outlook

The next 3-6 months will be crucial in determining whether Sat Kartar Life can successfully execute its transition to a healthcare-focused business model. The market will be watching for progress on the Jeena Sikho Lifecare partnership and expansion into Ayush-approved facilities.

Primary Thesis Risk

Failure to execute the transition to a healthcare-focused business model.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Excellent

Return on Equity (ROE)

32.04%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

39.66%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.39%

Annual dividend as % of current share price

Sat Kartar Valuation Check

Excellent

Price to Earnings (P/E)

20.28x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification

Small-cap

Higher growth potential with higher volatility.

Market Capitalisation

279.39 (Cr)

Total market value of all outstanding shares

Shareholding Pattern

Excellent

Promoter Holding

63.43%

% shares held by company founders/management

Poor

FII Holding

0.44%

% shares held by foreign institutional investors

Poor

DII Holding

3.10%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

103.93%

Net profit growth vs same quarter last year

Good

Revenue Growth (Quarterly YoY)

16.57%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.04x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

32.58x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Sat Kartar Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SATKARTAR across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Return on Equity (32.04%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (39.66%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 20.28 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (103.93%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (16.57%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.04)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (32.58x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (63.43%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 3.54%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Sat Kartar vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Sat Kartar with 10 other companies in the same sector

11 companies

Company Info	Fundamental Overall score	Valuation Price metrics	Profitability Return metrics		Financial Health Debt management	Growth 5Y performance		Dividend Yield %
Company Company name	Score Bull Run comprehensive fundamental score based on 20+ metrics	Price Current trading price of the stock	Market Cap Total value of all shares in the market	P/E Price per share divided by earnings per share	ROE Net income divided by shareholder equity	ROCE Earnings before interest and tax divided by capital employed	Debt/Eq Total debt divided by total equity	Profit 5Y Average annual profit growth over 5 years	Sales 5Y Average annual sales growth over 5 years	Dividend Annual dividend per share divided by price per share
Sat KartarSat Kartar...Selected✓ SATKARTAR •	47.7/100	₹177.45₹177	₹279.39₹279.39	20.28Average 20.3 Average	32.04%Excellent 32.04% Excellent	39.66%Excellent 39.66% Excellent	0.04Excellent 0.0 Excellent	— —	— —	0.39%
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715	65.2/100	₹1844.30₹1844	₹433738.68₹433738.68	37.57Average 37.6 Average	16.86%Good 16.86% Good	20.21%Excellent 20.21% Excellent	0.07Excellent 0.1 Excellent	23.78%Excellent 23.78% Excellent	9.87%Good 9.87% Good	0.89%
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488	67.9/100	₹6797.50₹6798	₹170445.88₹170445.88	68.59Average 68.6 Average	15.35%Good 15.35% Good	20.44%Excellent 20.44% Excellent	0.01Excellent 0.0 Excellent	10.41%Good 10.41% Good	11.65%Good 11.65% Good	0.47%
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420	65.3/100	₹4537.80₹4538	₹126430.62₹126430.62	58.36Average 58.4 Average	26.52%Excellent 26.52% Excellent	27.05%Excellent 27.05% Excellent	0.33Excellent 0.3 Excellent	13.84%Good 13.84% Good	7.72%Good 7.72% Good	0.86%
Cipla LtdCipla Ltd... CIPLA • 500087	59/100	₹1418.20₹1418	₹123059.76₹123059.76	22.62Average 22.6 Average	17.77%Good 17.77% Good	22.72%Excellent 22.72% Excellent	0.01Excellent 0.0 Excellent	28.68%Excellent 28.68% Excellent	9.97%Good 9.97% Good	0.85%
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124	59.2/100	₹1319.00₹1319	₹105224.96₹105224.96	18.23Average 18.2 Average	17.96%Good 17.96% Good	22.69%Excellent 22.69% Excellent	0.16Excellent 0.2 Excellent	22.28%Excellent 22.28% Excellent	13.26%Good 13.26% Good	0.63%
Lupin LtdLupin Ltd... LUPIN • 500257	66.7/100	₹2276.40₹2276	₹95148.15₹95148.15	22.00Average 22.0 Average	20.62%Excellent 20.62% Excellent	21.30%Excellent 21.30% Excellent	0.32Excellent 0.3 Excellent	54.88%Excellent 54.88% Excellent	8.11%Good 8.11% Good	0.58%
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321	68.7/100	₹956.95₹957	₹94253.78₹94253.78	18.74Average 18.7 Average	21.21%Excellent 21.21% Excellent	24.31%Excellent 24.31% Excellent	0.38Excellent 0.4 Excellent	25.92%Excellent 25.92% Excellent	10.27%Good 10.27% Good	1.17%
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904	50.6/100	₹2420.40₹2420	₹92012.53₹92012.53	52.62Average 52.6 Average	14.68%Average 14.68% Average	15.98%Good 15.98% Good	0.55Good 0.6 Good	11.73%Good 11.73% Good	15.79%Excellent 15.79% Excellent	0.04%
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804	28.8/100	₹1435.90₹1436	₹70798.69₹70798.69	20.69Average 20.7 Average	11.08%Average 11.08% Average	14.18%Average 14.18% Average	0.22Excellent 0.2 Excellent	3.87%Average 3.87% Average	6.55%Good 6.55% Good	0.33%
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523	59.5/100	₹5451.50₹5452	₹67075.29₹67075.29	28.54Average 28.5 Average	19.39%Good 19.39% Good	20.38%Excellent 20.38% Excellent	0.18Excellent 0.2 Excellent	13.93%Good 13.93% Good	9.21%Good 9.21% Good	0.80%

Top Pharmaceuticals Stocks

View all →

By Bull Run Score

By Return on Equity

Torrent Pharmaceuticals Ltd share price26.52%
Zydus Lifesciences Ltd share price21.21%
Lupin Ltd share price20.62%
Alkem Laboratories Ltd share price19.39%
Dr Reddys Laboratories Ltd share price17.96%

By Market Cap

Sun Pharmaceutical Industries Ltd share price433738.68 Cr
Divis Laboratories Ltd share price170445.88 Cr
Torrent Pharmaceuticals Ltd share price126430.62 Cr
Cipla Ltd share price123059.76 Cr
Dr Reddys Laboratories Ltd share price105224.96 Cr

Sat Kartar Quarterly Performance

Latest quarterly metrics for SATKARTAR — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

16.57%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

103.93%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Sat Kartar Financial Statements

Annual income statement, balance sheet and cash flow for Sat Kartar (SATKARTAR) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Sat Kartar

About SATKARTAR (Sat Kartar)

Sat Kartar (SATKARTAR) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current ma...rket capitalisation of ₹279.39 (Cr). Sat Kartar has delivered a Return on Equity (ROE) of 32.04% and a ROCE of 39.66%. The debt-to-equity ratio stands at 0.04, reflecting the company's capital structure. Investors tracking SATKARTAR share price can monitor key metrics including P/E ratio, promoter holding of 63.43%, and quarterly earnings growth.